Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 22.26% is 27% above its 5-year average of 17.55%, near the high end of its 5-year range (4.65%–22.63%).
As of the fiscal period ended Wednesday, December 31, 2025. 2.25% above its 12-month average of 21.77%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
22.26%
RETURN ON EQUITY (ROE) AVG TTM
21.77%
RETURN ON EQUITY (ROE) AVG 3Y
21.17%
RETURN ON EQUITY (ROE) AVG 5Y
17.55%
RETURN ON EQUITY (ROE) AVG 10Y
1.32%
RETURN ON EQUITY (ROE) AVG 15Y
0.49%
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+2.25%
CURRENT VS 3Y AVG
+5.15%
CURRENT VS 5Y AVG
+26.81%
CURRENT VS 10Y AVG
+1591.02%
CURRENT VS 15Y AVG
+4486.54%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+104.41%
vs the sector median at left
IQVIA Holdings Inc.
Market Cap
$34.72B
Return on Equity (ROE)
22.26%
TTM Avg
21.77%
3Y Avg
21.17%
5Y Avg
17.55%
Market Cap
$36.28B
Return on Equity (ROE)
53.68%
TTM Avg
-187.43%
3Y Avg
134.89%
5Y Avg
51.69%
Market Cap
$32.77B
Return on Equity (ROE)
8.55%
TTM Avg
9.02%
3Y Avg
4.86%
5Y Avg
4.86%
Market Cap
$31.59B
Return on Equity (ROE)
81.75%
TTM Avg
66.19%
3Y Avg
56.82%
5Y Avg
52.60%
Market Cap
$31.31B
Return on Equity (ROE)
-30.07%
TTM Avg
-10.46%
3Y Avg
-1.37%
5Y Avg
1.10%
Market Cap
$39.14B
Return on Equity (ROE)
19.85%
TTM Avg
20.59%
3Y Avg
21.51%
5Y Avg
20.54%
Market Cap
$29.85B
Return on Equity (ROE)
7.36%
TTM Avg
8.42%
3Y Avg
11.86%
5Y Avg
16.52%
Market Cap
$28.33B
Return on Equity (ROE)
23.41%
TTM Avg
22.23%
3Y Avg
22.34%
5Y Avg
21.79%
Market Cap
$27.61B
Return on Equity (ROE)
31.47%
TTM Avg
28.93%
3Y Avg
25.01%
5Y Avg
22.95%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IQVIA Holdings Inc. (IQV) | $34.72B | 22.26% | 21.77% | 21.17% | 17.55% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $36.28B | 53.68% | -187.43% | 134.89% | 51.69% |
| Medline Inc. (MDLN)vs › | $32.77B | 8.55% | 9.02% | 4.86% | 4.86% |
| Zoetis Inc. (ZTS)vs › | $31.59B | 81.75% | 66.19% | 56.82% | 52.60% |
| Centene Corp. (CNC)vs › | $31.31B | -30.07% | -10.46% | -1.37% | 1.10% |
| Agilent Technologies, Inc. (A)vs › | $39.14B | 19.85% | 20.59% | 21.51% | 20.54% |
| Biogen Inc. (BIIB)vs › | $29.85B | 7.36% | 8.42% | 11.86% | 16.52% |
| ResMed Inc. (RMD)vs › | $28.33B | 23.41% | 22.23% | 22.34% | 21.79% |
| DexCom, Inc. (DXCM)vs › | $27.61B | 31.47% | 28.93% | 25.01% | 22.95% |
| GE HealthCare Technologies Inc. (GEHC)vs › | $27.56B | 14.11% | 21.84% | 21.53% | 32.27% |
ROE
22.3%
ROA
4.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 20.91% |
| 2024-12-31 | 22.63% |
| 2023-12-31 | 22.22% |
| 2022-12-31 | 18.92% |
| 2021-12-31 | 15.99% |
| 2020-12-31 | 4.65% |
| 2019-12-31 | 3.18% |
| 2018-12-31 | 3.86% |
| 2017-12-31 | 16.14% |
| 2016-12-31 | 1.33% |
| 2015-12-31 | -115.35% |
| 2014-12-31 | -50.62% |
| 2013-12-31 | -33.95% |
| 2012-12-31 | -13.06% |
| 2011-12-31 | -24.92% |
| 2010-12-31 | 0.00% |
